Top

Orphanet Journal of Rare Diseases

Published in:

01-12-2021 | Pruritus | Review

Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review

Authors: Tracey Jones-Hughes, Jo Campbell, Louise Crathorne

Published in: Orphanet Journal of Rare Diseases | Issue 1/2021

Abstract

Background

Progressive familial intrahepatic cholestasis is a rare, heterogeneous group of liver disorders of autosomal recessive inheritance, characterised by an early onset of cholestasis with pruritus and malabsorption, which rapidly progresses, eventually culminating in liver failure. For children and their parents, PFIC is an extremely distressing disease. Significant pruritus can lead to severe cutaneous mutilation and may affect many activities of daily living through loss of sleep, irritability, poor attention, and impaired school performance.

Methods

Databases including MEDLINE and Embase were searched for publications on PFIC prevalence, incidence or natural history, and the economic burden or health-related quality of life of patients with PFIC. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.

Results

Three systematic reviews and twenty-two studies were eligible for inclusion for the epidemiology of PFIC including a total of 2603 patients. Study periods ranged from 3 to 33 years. Local population prevalence of PFIC was reported in three studies, ranging from 9.0 to 12.0% of children admitted with cholestasis, acute liver failure, or splenomegaly. The most detailed data come from the NAPPED study where native liver survival of >15 years is predicted in PFIC2 patients with a serum bile acid concentration below 102 µmol/L following bile diversion surgery. Burden of disease was mainly reported through health-related quality of life (HRQL), rates of surgery and survival. Rates of biliary diversion and liver transplant varied widely depending on study period, sample size and PFIC type, with many patients have multiple surgeries and progressing to liver transplant. This renders data unsuitable for comparison.

Conclusion

Using robust and transparent methods, this systematic review summarises our current knowledge of PFIC. The epidemiological overview is highly mixed and dependent on presentation and PFIC subtype. Only two studies reported HRQL and mortality results were variable across different subtypes. Lack of data and extensive heterogeneity severely limit understanding across this disease area, particularly variation around and within subtypes.

Available only for authorised users

Gunaydin M, Cil ATB. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med. 2018;10:95.PubMedPubMedCentralCrossRef

Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol. 2010;53(1):170–8.PubMedPubMedCentralCrossRef

Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014;4(1):25–36.PubMedCrossRef

Mehl A, Bohorquez H, Serrano M-S, Galliano G, Reichman TW. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant. 2016;6(2):278.PubMedPubMedCentralCrossRef

Baker A, Kerkar N, Todorova L, Kamath BM, Houwen RH. Systematic review of progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2019;43(1):20–36.PubMedCrossRef

The Joanna Briggs Institute. Checklist for prevalence studies [Available from: http://joannabriggs.org/research/critical-appraisal-tools.html.

Davis AR, Rosenthal P, Newman TB. Nontransplant surgical interventions in progressive familial intrahepatic cholestasis. J Pediatr Surg. 2009;44(4):821–7.PubMedCrossRef

Verkade HJ, Thompson RJ, Arnell H, Fischler B, Gillberg PG, Mattsson JP, et al. Systematic review and meta-analysis: partial external biliary diversion in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2020;71(2):176–83.PubMedCrossRef

Foroutan HR, Bahador A, Ghanim SM, Dehghani SM, Anbardar MH, Fattahi MR, et al. Effects of partial internal biliary diversion on long-term outcomes in patients with progressive familial intrahepatic cholestasis: experience in 44 patients. Pediatr Surg Int. 2020;36(5):603–10.PubMedCrossRef

10.

Van Vaisberg V, Tannuri ACA, Lima FR, Tannuri U. Ileal exclusion for pruritus treatment in children with progressive familial intrahepatic cholestasis and other cholestatic diseases. J Pediatr Surg. 2020;55(7):1385–91.PubMedCrossRef

11.

van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020;73(1):84–93.PubMedCrossRef

12.

Thebaut A, Habes D, Gottrand F, Rivet C, Cohen J, Debray D, et al. Sertraline as an additional treatment for cholestatic pruritus in children. J Pediatr Gastroenterol Nutr. 2017;64(3):431–5.PubMedCrossRef

13.

Valamparampil J, Shanmugam N, Reddy MS, Rela M. Liver transplantation in progressive familial intrahepatic cholestasis: outcome analysis from a single centre. Transplantation. 2018;102(5 Supplement 1):141–2.

14.

Van Wessel D, Thompson RJ, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. The natural course of BSEP deficiency: Results from the global napped-consortium. Hepatol. 2018;68(Supplement 1):117A-A118.

15.

Van Wessel D, Thompson RJ, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. The natural course of fic1 deficiency: Results from the napped-consortium. Hepatol. 2018;68(Supplement 1):1051A-A1052.

16.

Van Wessel D, Thompson R, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. The natural course of FIC1 deficiency and BSEP deficiency: Initial results from the NAPPEDconsortium (NAtural course andprognosis of PFIC and effect of biliary diversion). J Pediatr Gastroenterol Nutr. 2018;66(Supplement 2):650–2.

17.

Van Wessel D, Thompson R, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. The natural course of FIC1 deficiency and BSEP deficiency: Initial results from the NAPPED-consortium (Natural course and Prognosis of PFIC and Effect of biliary Diversion). J Hepatol. 2018;68(Supplement 1):S626–7.CrossRef

18.

Van Wessel D, Thompson R, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. Factors associated with the natural course of disease in patients with FIC1-deficiency: The NAPPED-consortium. J Pediatr Gastroenterol Nutr. 2019;68(Supplement 1):688–9.

19.

20.

Acar S, Demir B, Ayyildiz H, Polat KY, Kanmaz T, Akyildiz M, et al. Living donor liver transplantation for PFIC type 3. J Pediatr Gastroenterol Nutr. 2019;68(Supplement 1):918.

21.

Flores CD, Yu YR, Miloh TA, Goss J, Brandt ML. Surgical outcomes in alagille syndrome and PFIC: a single institution’s 20-year experience. J Pediatr Surg. 2018;53(5):976–9.PubMedCrossRef

22.

Valamparampil JJ, Rinaldhy K, Reddy MS, Shanmugam N, Rela M. Outcomes of liver transplantation for pediatric recipients with progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2019;9(3):422–3.CrossRef

23.

24.

Wang KS, Tiao G, Bass LM, Hertel PM, Mogul D, Kerkar N, et al. Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatol. 2017;(no pagination).

25.

Malik HS, Cheema HA, Hashmi MA, Waheed N, Anwar A, Anjum MN. Frequency of hepato-biliary disorders in children presenting at the children’s hospital & the institute of child health, lahore, a tertiary care referral center. Pak Paed J. 2017;41(1):42–8.

26.

Meena BL, Khanna R, Sharma CB, Rawat D, Alam S. Ductal paucity in childhood: spectrum, profile and outcome. Hepatol Int. 2017;11(1 Supplement 1):S366.

27.

Morris AL, Bukauskas K, Sada RE, Shneider BL. Byler disease: early natural history. J Pediatr Gastroenterol Nutr. 2015;60(4):460–6.PubMedCrossRef

28.

Schatz SB, Jungst C, Keitel-Anselmo V, Kubitz R, Becker C, Gerner P, et al. Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset. Hepatol Commun. 2018;2(5):504–14.PubMedPubMedCentralCrossRef

29.

Ruth N, Sharif K, McGovern-Weijers A, Hartley J, Van Mourik I, Kelly D, et al. Long term outcome of children with PFIC-A single centre experience. J Pediatr Gastroenterol Nutr. 2018;66(Supplement 2):793–4.

30.

Alhebbi H, Alhafaf F, Alqahtani A, Algubaisi S, Wali S. 391 Genetically confirmed familial cholestatic liver disorders in Saudi Arabia, a 22 years single center experience. J Pediatr Gastroenterol Nutr. 2020;71:S258.

31.

Thompson RJ, Kelly D, Miethke A, Rajwal S, Soufi N, Jankowska I, et al. LBO08 Serum bile acid control in long-term maralixibat-treated patients is associated with native liver survival in children with progressive familial intrahepatic cholestasis due to bile salt export pump deficiency (S120). J Hepatol. 2020;73:S99–122.CrossRef

32.

Bjornland K, Hukkinen M, Gatzinsky V, Arnell H, Pakarinen MP, Almaas R, et al. Partial Biliary Diversion May Promote Long-Term Relief of Pruritus and Native Liver Survival in Children with Cholestatic Liver Diseases. Eur J Pediatr Surg. 2020.

33.

Kamath BM, Chen Z, Romero R, Fredericks EM, Alonso EM, Arnon R, et al. Quality of life and its determinants in a multicenter cohort of children with Alagille syndrome. J Pediat. 2015;167(2):390–6. e3.

34.

Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. Acta Paediatr. 2001;90(1):88–92.PubMedCrossRef

35.

Ruth N, Gray Z, McKay K, Lloyd C, Hartley J, MacDonald F, et al. Identifying incidence of inherited metabolic disorders in patients with infantile liver disease. J Hepatol. 2014;60:505.CrossRef

36.

Al Mehaidib A, Al SA. 1381 progressive familial intrahepatic cholestasis in ARABS. J Hepatol. 2013;58:S555–6.CrossRef

37.

Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatol. 2010;51(5):1645–55.CrossRef

38.

Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation. 2007;84(10):1361–3.PubMedCrossRef

39.

Henriksen N, Drabløs P, Aagenaes O. Cholestatic jaundice in infancy. The importance of familial and genetic factors in aetiology and prognosis. Arch Dis Childh. 1981;56(8):622–7.

40.

Miyagawa-Hayashino A, Egawa H, Yorifuji T, Hasegawa M, Haga H, Tsuruyama T, et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. World J Transplant. 2009;15(6):610–8.

41.

Hori T, Egawa H, Takada Y, Ueda M, Oike F, Ogura Y, et al. Progressive familial intrahepatic cholestasis: a single-center experience of living-donor liver transplantation during two decades in Japan. Clin Transplant. 2011;25(5):776–85.PubMedCrossRef

42.

Lee W, Chai P, Looi L. Progressive familial intrahepatic cholestasis in Malaysian patients—a report of five cases. Med J Malaysia. 2009;64(3):216–9.PubMed

43.

Nielsen I, Eiberg H. Cholestasis Familiaris Groelandica: an epidemiological, clinical and genetic study. Int J Circumpolar Health. 2004;63(sup2):192–4.PubMedCrossRef

44.

Wanty C, Joomye R, Van NH, Paul K, Otte J-B, Reding R, et al. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol. 2004;67(4):313–9.

45.

Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 1994;18(2):134–41.PubMedCrossRef

46.

Wassman S, Pfister ED, Kuebler JF, Ure BM, Goldschmidt I, Dingemann J, et al. Quality of life in patients with progressive familial intrahepatic cholestasis: No difference between post-liver transplantation and post-partial external biliary diversion. J Pediatr Gastroenterol Nutr. 2018;67(5):643–8.PubMedCrossRef

47.

Yee K, Moshkovich O, Llewellyn S, Benjamin K, Desai NK. A web-based survey of itch severity after surgical treatment of progressive familial intrahepatic cholestasis in children and adolescents. Hepatol. 2018;68(Supplement 1):1047A.

48.

Arnell H, Bergdahl S, Papadogiannakis N, Nemeth A, Fischler B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg. 2008;43(7):1312–20.PubMedCrossRef

49.

Aydogdu S, Cakir M, Arikan C, Tumgor G, Yuksekkaya HA, Yilmaz F, et al. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth. Pediatr Transplant. 2007;11(6):634–40.PubMedCrossRef

50.

Emond JC, Whitington PF. Selective surgical management of progressive familial intrahepatic cholestasis (Byler’s disease). J Pediatr Surg. 1995;30(12):1635–41.PubMedCrossRef

51.

Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatol. 1997;25(3):519–23.CrossRef

52.

Jankowska I, Czubkowski P, Kalicinski P, Ismail H, Kowalski A, Ryzko J, et al. Ileal exclusion in children with progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2014;58(1):92–5.PubMedCrossRef

53.

Wanty C, Joomye R, Van Hoorebeek N, Paul K, Otte JB, Reding R, et al. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol. 2004;67(4):313–9.

54.

Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr Int. 1999;41(6):662–5.PubMedCrossRef

55.

van Wessel D, Thompson R, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipin?ski P, et al. Predicting long-term outcome after surgical biliary diversion in Bsep-deficiency patients: Results from the NAPPED consortium. J Hepatol. 2019;70(1):e121.

56.

Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr Transplant. 1999;3(3):219–24.PubMedCrossRef

57.

Schukfeh N, Metzelder ML, Petersen C, Reismann M, Pfister ED, Ure BM, et al. Normalization of serum bile acids after partial external biliary diversion indicates an excellent long-term outcome in children with progressive familial intrahepatic cholestasis. J Pediatr Surg. 2012;47(3):501–5.PubMedCrossRef

58.

Bull LN, Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Dodge JL, et al. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun. 2018;2(5):515–28.PubMedPubMedCentralCrossRef

59.

Halaweish I, Chwals WJ. Long-term outcome after partial external biliary diversion for progressive familial intrahepatic cholestasis. J Pediatr Surg. 2010;45(5):934–7.PubMedCrossRef

60.

Van Wessel D, Thompson R, Grammatikopoulos T, Kadaristiana A, Jankowska I, Lipinski P, et al. Predicting long-term outcome after surgical biliary diversion in BSEP-deficiency patients: Results from the NAPPED consortium. J Pediatr Gastroenterol Nutr. 2019;68(Supplement 1):702–3.

61.

Agarwal S, Lal BB, Rawat D, Rastogi A, Bharathy KGS, Alam S. Progressive familial intrahepatic cholestasis (PFIC) in Indian Children: clinical spectrum and outcome. J Clin Exp Hepatol. 2016;6(3):203–8.PubMedPubMedCentralCrossRef

62.

Cantez MS, Onal Z, Guller D, Ekici F, Gulluoglu M, Soysal FG, et al. Diverse mutations and different clinical outcomes in children with progressive intrahepatic cholestasis. J Pediatr Gastroenterol Nutr. 2018;66(Supplement 2):723.

63.

Chen L, Xiao H, Ren X-H, Li L. Long-term outcomes after cholecystocolostomy for progressive familial intrahepatic cholestasis. Hepatol Res. 2018;48(13):1163–71.PubMedCrossRef

64.

Erginel B, Soysal FG, Durmaz O, Celik A, Salman T. Long-term outcomes of six patients after partial internal biliary diversion for progressive familial intrahepatic cholestasis. J Pediatr Surg. 2018;53(3):468–71.PubMedCrossRef

65.

Nielsen IM, Eiberg H. Cholestasis Familiaris Groenlandica: an epidemiological, clinical and genetic study. Int J Circumpolar Health. 2004;63(Suppl 2):192–4.PubMedCrossRef

66.

Varma S, Revencu N, Stephenne X, Scheers I, Smets F, Beleza-Meireles A, et al. Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2. Hepatol. 2015;62(1):198–206.CrossRef

Title: Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review
Authors: Tracey Jones-Hughes
Jo Campbell
Louise Crathorne
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Pruritus
Published in: Orphanet Journal of Rare Diseases / Issue 1/2021
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-021-01884-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Epidemiology and burden of progressive familial intrahepatic cholestasis: a systematic review

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum

Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies

Hyperpigmented spots at fundus examination: a new ocular sign in Neurofibromatosis Type I

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis

The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study

Clinical features of lupus enteritis: a single-center retrospective study